Navigation Links
U-M Researchers Receive $1.8 Million Grant to Develop New Therapy for Neuropathic Pain
Date:11/9/2009

Neurologists will use funds to move lab findings into human therapy for difficult-to-treat condition that involves pain from nerve damage

ANN ARBOR, Mich., Nov. 9 /PRNewswire-USNewswire/ --Researchers from the University of Michigan Department of Neurology have received a $1.8 million grant to develop a novel therapy for neuropathic pain, a difficult-to-treat condition in which patients experience pain because of damage to nerve without obvious tissue injury.

In previously published studies, these investigators have found that gene transfer to sensory nerves using a modified herpes simplex virus-based vector effectively reduced pain-related behaviors in rodents with nerve damage caused by trauma or diabetes. A gene transfer vector is an agent used to carry genes into cells.

The newly awarded grant from the Department of Veterans Affairs will allow the investigators to produce and certify a human grade vector that will then be tested in patients with pain from nerve damage resulting from diabetes.

"This grant will allow us to take the critical step in translating laboratory findings into human therapy," says principal investigator David Fink, M.D., Robert Brear professor and chair of the Department of Neurology. Fink is also a staff neurologist at the VA Ann Arbor Healthcare System.

Fink and his collaborators have previously demonstrated that gene transfer vectors created from recombinant crippled herpes simplex viruses can be used to deliver genes to sensory nerves from application in the skin.

Fink is directing a phase 1 human trial on the first such vector carrying the gene for human preproenkephalin in patients with intractable pain from cancer. The second trial will test a vector carrying the gene for glutamic acid decarboxylase that has proven to be particularly effective in animal models of neuropathic pain.

"We are very excited to receive this grant," says co-investigator Dr. Marina Mata, M.D., also a professor of Neurology.

"We routinely create new vectors and produce them in the laboratory for animal studies, but in order to have a vector that is approved for human use requires a series of extraordinarily expensive steps. This grant should allow us to begin the human trial in patients with painful diabetic neuropathy within two years."

Construction of the vector will be carried out under contract by Diamyd, Inc. of Pittsburgh, PA. Diamyd is funding the phase 1 trial of the preproenkephalin vector, and has licensed the patents to the vector technology.

The researchers believe that the use of HSV vectors holds promise not only for the treatment of pain but also ultimately for the treatment of peripheral neuropathy itself.

Fink has received research funding from Diamyd related to the human trial of the preproenkephalin vector. He has no equity interest in nor any consulting agreements with Diamyd.

SOURCE University of Michigan Health System


'/>"/>
SOURCE University of Michigan Health System
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers show how to divide and conquer social network of cells
2. Connection between depression and osteoporosis detailed by Hebrew University researchers
3. Researchers find new way to attack inflammation in Graves eye disease
4. Jefferson researchers receive $3.9 million in Challenge grants
5. Childhood cancer survivors less likely to marry, Yale researchers find
6. Researchers unlock the sound of learning by linking sensory and motor systems
7. Researchers identify the 3 killer indicators that are even worse than high cholesterol
8. Researchers discover links between city walkability and air pollution exposure
9. High-definition colonoscopy detects more polyps, Mayo Clinic researchers say
10. Researchers find room design can enhance patient care
11. UC San Diego researchers reverse pulmonary arterial hypertension in mouse models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... “The Journey: From the Mountains to the Mission Field”: ... souls in the Philippines. “The Journey: From the Mountains to the Mission Field” is ... Bible. She has taught all ages and currently teaches a class of ladies at ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
Breaking Medicine Technology: